CClinicalTrials.gg
CompletedNCT01911260APZincUpdated Dec 24, 2013Results posted

Weekly Zinc Chelate Supplementation on Children's Growth

A Phase 2/3 interventional study of Zinc amino acid chelate and Placebo in Short Stature, sponsored by Federal University of São Paulo. Completed. Open to participants aged 7 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-12-24.

Sponsored by Federal University of São Paulo · Phase 2/3, Interventional, and Prevention

Phase
Phase 2/3
Study type
Interventional
Enrollment
199
Allocation
Randomized
Ages
7 Years to 10 Years
Sex
All
01

Study summary

The purpose of this study is to measure the effect of weekly zinc supplementation on schoolchildren with growth deficit or normal stature.

Read the detailed description

Zinc is an important micronutrient for humans. Trials with zinc have shown positive effects of supplementation on growth, but there is still a lack of results on schoolchildren population. This Randomized Double-Blind Controlled Trial was design to measure the effect of weekly zinc supplementation on schoolchildren with growth deficit and normal stature. Schoolchildren were allocated into two homogeneous groups named Growth Deficit (HAZ \< -1,5 Z-score), and Normal Stature (HAZ between -1,0 and ±1,0 Z-score) and were randomly assigned to compose two exposed and two control groups to receive a supplement of 30mg of zinc amino acid chelate or placebo individually once a week, during 12 weeks. Children's heights were measured at the end of supplementation period and again after 12 weeks.

02

Conditions studied

  • Short Stature

Browse trials for

Keywords

  • Zinc
  • Growth
  • Child
  • Dietary Supplements
  • Randomized Controlled Trial
03

In context

Dwarfism

125 studies on the registry are indexed under Dwarfism; 19 are open to participants now.

This study's enrollment of 199 is above the median of 75 across 74 interventional studies indexed under Dwarfism.

Browse Dwarfism studies →

Lead sponsor

Federal University of São Paulo is the lead sponsor of 427 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
7 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD). For the Normal Stature group(NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.

Exclusion criteria

Exclusion Criteria:

  • Children of GD group were evaluated by a Pediatrician specialized in growth disorders with the objective of excluding any organic or genetic condition correlated with growth deficit.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
199 participants (actual)

Study arms

  • Active comparator
    Growth Deficit+zinc amino acid chelate

    Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD). During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.

    Dietary Supplement: Zinc amino acid chelate

  • Placebo comparator
    Growth Deficit receiving placebo

    Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD). During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.

    Other: Placebo

  • Placebo comparator
    Normal Height receiving placebo

    For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex. During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.

    Other: Placebo

  • Active comparator
    Normal Height+zinc amino acid chelate

    For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex. During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.

    Dietary Supplement: Zinc amino acid chelate

Interventions

  • Dietary supplementZinc amino acid chelate

    During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.

  • OtherPlacebo

    During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.

06

What researchers measure

Primary outcomes

  1. Change in Height-for-Age Z-score (HAZ) From End of Supplementation to End of Follow-up Period.

    Schoolchildren were allocated into two homogeneous groups named Growth Deficit (HAZ \< -1,5 Z-score), and Normal Height (HAZ between -1,0 and ±1,0 Z-score), and were randomly assigned to compose two exposed groups to receive a supplement of 30mg of zinc amino acid chelate, and two control groups to receive placebo individually once a week, during 12 weeks. Children's heights were measured at the End of Supplementation period and again after 12 weeks (Follow-up period). In combination with sex and age we transformed stature to Height-for-Age, expressed in Z-score, which was calculated as a number of standard deviations or Z-scores below or above the reference mean or median value, according to the formula below: Z-score = (observed value - median value of the reference population) / standard deviation value of reference population. We analyzed and discussed the change in HAZ (HAZ at the End of Follow-up period - HAZ at End of Supplementation).

    Time frame: Height-for-Age Z-score was measured at the End of Supplementation period and again at the End of Follow-up period, with a 12 weeks interval.

07

Results

Posted Dec 24, 2013
Limitations and caveats
The sample loss is a factor that hinders the adoption of results as definitive. Even if they remained similar according to biodemographic variables, we cannot guarantee the maintenance of group equality defined in randomization.

Participant flow

From original database of 2.519 children, enrolled in the first and second grades of four State-run public basic schools, we selected this study sample using height for age indicator (HAZ). Meetings were held at school with parents/guardians to explain the objective and procedures of the study in order to obtain a written consent.

Supplementation Period
Participant flow — Supplementation Period
MilestoneGrowth Deficit+Zinc Amino Acid ChelateGrowth Deficit + PlaceboNormal Height+Zinc Amino Acid ChelateNormal Height + Placebo
Started50504950
Completed40383942
Not completed1012108
Withdrew: Transference or evasion of school7976
Withdrew: Adverse event2010
Withdrew: Refused to receive supplement1010
Withdrew: Less than 12 weeks supplementation0312
Follow-up Period
Participant flow — Follow-up Period
MilestoneGrowth Deficit+Zinc Amino Acid ChelateGrowth Deficit + PlaceboNormal Height+Zinc Amino Acid ChelateNormal Height + Placebo
Started40383942
Completed27182430
Not completed13201512
Withdrew: Transference or evasion of school13201512

Outcome measures

PrimaryChange in Height-for-Age Z-score (HAZ) From End of Supplementation to End of Follow-up Period.

Schoolchildren were allocated into two homogeneous groups named Growth Deficit (HAZ \< -1,5 Z-score), and Normal Height (HAZ between -1,0 and ±1,0 Z-score), and were randomly assigned to compose two exposed groups to receive a supplement of 30mg of zinc amino acid chelate, and two control groups to receive placebo individually once a week, during 12 weeks. Children's heights were measured at the End of Supplementation period and again after 12 weeks (Follow-up period). In combination with sex and age we transformed stature to Height-for-Age, expressed in Z-score, which was calculated as a number of standard deviations or Z-scores below or above the reference mean or median value, according to the formula below: Z-score = (observed value - median value of the reference population) / standard deviation value of reference population. We analyzed and discussed the change in HAZ (HAZ at the End of Follow-up period - HAZ at End of Supplementation).

Time frame:
Height-for-Age Z-score was measured at the End of Supplementation period and again at the End of Follow-up period, with a 12 weeks interval.
Reported as:
Mean · Z-Score
Change in Height-for-Age Z-score (HAZ) From End of Supplementation to End of Follow-up Period.
Z-ScoreGrowth Deficit+Zinc Amino Acid ChelateGrowth Deficit + PlaceboNormal Height+Zinc Amino Acid ChelateNormal Height + Placebo
Change in Height-for-Age Z-score (HAZ) From End of Supplementation to End of Follow-up Period.0.04 ± 0.12-0.08 ± 0.450.10 ± 0.150.02 ± 0.26
Statistical analysis
  • Growth Deficit+Zinc Amino Acid Chelate vs Growth Deficit + Placebo · t-test, 2 sided · p = <0.05 · Mean difference (final values): 0.12In intragroup of supplementation (zinc or placebo) we used the t-test for dependent samples in order to compare growth over time.
  • Normal Height+Zinc Amino Acid Chelate vs Normal Height + Placebo · t-test, 2 sided · p = <0.05 · Mean difference (final values): 0.08In intragroup of supplementation (zinc or placebo) we used the t-test for dependent samples in order to compare growth over time.

Adverse events

Collected over Adverse event data were collected during 12 weeks.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Growth Deficit+Zinc Amino Acid Chelate—0/50 (0%)2/50 (4%)
Growth Deficit Receiving Placebo—0/50 (0%)0/50 (0%)
Normal Height+Zinc Amino Acid Chelate—0/49 (0%)1/49 (2%)
Normal Height Receiving Placebo—0/50 (0%)0/50 (0%)
Most frequent other events
Most frequent other events
EventGrowth Deficit+Zinc Amino Acid ChelateGrowth Deficit Receiving PlaceboNormal Height+Zinc Amino Acid ChelateNormal Height Receiving Placebo
Gastrointestinal eventGastrointestinal disorders2/500/501/490/50

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Growth Deficit+Zinc Amino Acid ChelateGrowth Deficit + PlaceboNormal Height+Zinc Amino Acid ChelateNormal Height + PlaceboTotal
<=18 years50504950199
Between 18 and 65 years00000
>=65 years00000
Age Continuous
Age Continuous(years)Growth Deficit+Zinc Amino Acid ChelateGrowth Deficit + PlaceboNormal Height+Zinc Amino Acid ChelateNormal Height + PlaceboTotal
Mean7.63 ± 0.667.64 ± 0.717.63 ± 0.667.64 ± 0.717.63 ± 0.68
Sex: Female, Male
Sex: Female, Male(Participants)Growth Deficit+Zinc Amino Acid ChelateGrowth Deficit + PlaceboNormal Height+Zinc Amino Acid ChelateNormal Height + PlaceboTotal
Female2525242599
Male25252525100
Region of Enrollment
Region of Enrollment(participants)Growth Deficit+Zinc Amino Acid ChelateGrowth Deficit + PlaceboNormal Height+Zinc Amino Acid ChelateNormal Height + PlaceboTotal
Brazil50504950199
08

Study locations

No study locations are listed for this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01911260
Lead sponsor
Federal University of São Paulo
Responsible party
Ana Paula Poblacion (Master in Science, Federal University of São Paulo) — Principal investigator
First posted
Jul 30, 2013
Start date
Sep 2000
Primary completion
Dec 2000
Completion
Mar 2001
Results posted
Dec 24, 2013
Last update
Dec 24, 2013

Study contacts

José Augusto AC Taddei, MD, Dr PH
study director · Federal University of São Paulo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion